Comparison of the Effect of Sertraline and Escitalopram on the Treatment of Major Depressive Disorder in Hemodialysis Patients: A Randomized Controlled Trial
Novelty in Biomedicine,
Vol. 12 No. 4 (2024),
28 September 2024
,
Page 149-155
https://doi.org/10.22037/nbm.v12i4.45198
Abstract
Background: We decided to compare the effects of sertraline and escitalopram in the treatment of major depressive disorder in hemodialysis patients.
Materials and Methods: In this single-blind randomized clinical trial, 100 patients with End-Stage Renal Disease (ESRD) undergoing hemodialysis with a Beck Depression Inventory (BDI) score greater than 15 who were not using medication for depression were included in the study. Then randomly assigned to two groups: (one receiving sertraline and one receiving escitalopram). Both groups were monitored using the Beck questionnaire at the end of the first, second, and third months. Additionally, side effects, treatment compliance, and mortality were compared between the two groups.
Results: In total, 100 patients with ESRD were included in the study (48 in the sertraline treatment group and 52 in the escitalopram treatment group). The results indicate that in both treatment groups, depression rates significantly decreased over time with medication (P<0.001). Comparing the depression scores over time revealed that the effect of sertraline and escitalopram in reducing depression was not significantly different. However, the depression score in the sertraline group was slightly lower than that in the escitalopram group, although this difference was not statistically significant. Side effects, treatment compliance, and mortality were comparable between the two groups.
Conclusion: In general, both sertraline and escitalopram significantly reduced the score of depression in patients, but sertraline in reducing the depression score was greater than that of escitalopram, although this difference was not significant.
- Depression
- Hemodialysis
- Escitalopram
- Sertraline
How to Cite
References
Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. American Journal of Kidney Diseases. 2020;75(1):A6–7.
Palmer SC, Natale P, Ruospo M, Saglimbene VM, Rabindranath KS, Craig JC, et al. Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. Cochrane Database Syst Rev. 2016;2016(5):CD004541.
Ma TK, Li PK. Depression in dialysis patients. Nephrology. 2016;21(8):639–46.
Bautovich A, Katz I, Smith M, Loo CK, Harvey SB. Depression and chronic kidney disease: A review for clinicians. Australian & New Zealand Journal of Psychiatry. 2014;48(6):530–41.
Cohen SD, Norris L, Acquaviva K, Peterson RA, Kimmel PL. Screening, Diagnosis, and Treatment of Depression in Patients with End-Stage Renal Disease. Clinical Journal of the American Society of Nephrology. 2007;2(6):1332–42.
Wolman BB. Dictionary of behavioral science, New York (Van Nostrand Reinhold Company) 1973.
DSM-5 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Arlington: American Psychiatric Publishing. 2013; 10.
Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005;510(1–2):49–57.
Constantino JL, Fonseca VA. Pharmacokinetics of antidepressants in patients undergoing hemodialysis: a narrative literature review. Brazilian Journal of Psychiatry. 2019;41(5):441–6.
Fasipe OJ. Neuropharmacological classification of antidepressant agents based on their mechanisms of action. Archives of Medicine and Health Sciences. 2018 Jan 1; 6(1):81.
Nadort E, Schouten RW, Witte SHS, Broekman BFP, Honig A, Siegert CEH, et al. Treatment of current depressive symptoms in dialysis patients: A systematic review and meta-analysis. Gen Hosp Psychiatry. 2020;67:26–34.
Mackay FJ, Dunn NR, Wilton L V, Pearce GL, Freemantle SN, Mann RD. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf. 1997;6(4):235–46.
Mehrotra R, Cukor D, Unruh M, Rue T, Heagerty P, Cohen SD, et al. Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis. Ann Intern Med. 2019;170(6):369.
Crépeau-Gendron G, Brown HK, Shorey C, Madan R, Szabuniewicz C, Koh S, et al. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. J Affect Disord. 2019;250:341–5.
Jassal S V., Watson D. Dialysis in Late Life. Clinical Journal of the American Society of Nephrology. 2009;4(12):2008–12.
Lopes AA, Bragg-Gresham JL, Satayathum S, McCullough K, Pifer T, Goodkin DA, et al. Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases. 2003;41(3):605–15.
Friedli K, Guirguis A, Almond M, Day C, Chilcot J, Da Silva-Gane M, et al. Sertraline Versus Placebo in Patients with Major Depressive Disorder Undergoing Hemodialysis: A Randomized, Controlled Feasibility Trial. Clin J Am Soc Nephrol. 2017 Feb 7;12(2):280–6.
Naik BL, Babu N G. Efficacy and tolerability of escitalopram in patients with chronic kidney disease undergoing hemodialysis having depressive disorder. Indian J Psychiatry. 2022; 64 (Suppl 3):S556–7.
Kubanek A, Paul P, Przybylak M, Kanclerz K, Rojek JJ, Renke M, et al. Use of Sertraline in Hemodialysis Patients. Medicina (B Aires). 2021;57(9):949.
Mehrotra R, Cukor D, Unruh M, Rue T, Heagerty P, Cohen SD, et al. Comparative efficacy of therapies for treatment of depression for patients undergoing maintenance hemodialysis: a randomized clinical trial. Annals of internal medicine. 2019 Mar 19; 170(6):369-79.
Yin J, Song X, Wang C, Lin X, Miao M. Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2023;23(1):876.
Nagler E V, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736–45.
Hosseini SH, Espahbodi F, Mirzadeh Goudarzi SMM. Citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients. Iran J Kidney Dis. 2012;6(6):446–51.
Atalay H, Solak Y, Biyik M, Biyik Z, Yeksan M, Uguz F, et al. Sertraline treatment is associated with an improvement in depression and health-related quality of life in chronic peritoneal dialysis patients. Int Urol Nephrol. 2010;42(2):527–36.
Turk S, Atalay H, Altintepe L, Güney I, Okudan N, Tonbul HZ, et al. Treatment with antidepressive drugs improved quality of life in chronic hemodialysis patients. Clin Nephrol. 2006;65(2):113–8.
Assimon MM, Brookhart MA, Flythe JE. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis. Journal of the American Society of Nephrology. 2019;30(4):611–23.
- Abstract Viewed: 121 times
- pdf Downloaded: 110 times